Ipca Laboratories Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i0y0ns91v79e6m9jx25xxe2j.pdf

Key Takeaways


Domestic Formulations: The Quarter’s Engine


Export Formulations: Geopolitics and a UK Reset

A. K. Jain: "In fact, we are sensing that business would definitely go up there. There are good opportunities, our team is working, the team is right now setting from India there to assess all those kind of things which are other dossiers, which are other markets on which we can get Russian approvals..."

API Business: Impurity Fallout and Price Uncertainty

A. K. Jain: "Let us say, issue got resolved, we have filed the newer process, whatever with modifications and all, but lot of shipments which were made earlier to certain geographies, they have return back, so sales return was higher."
Harish Kamath: "Yes, that is correct, but whatever benefit we have costing and other things, we are sure we will get back all our customers and all our volume, but it will a slow progress..."

Margins: Cost Pressures and a Provision

A. K. Jain: "We are seeing the softening of the prices of certain, the key intermediates in the recent time and probably that trend would continue. So, if that trend continues, then overall our gross margin will further restore."

Capital Projects: Dewas, Ratlam, and the Lyka Journey

A. K. Jain: "We don't foresee any kind of significant impact of Dewas coming in the current financial year. Dewas will start impacting our overall performance, may be from the second quarter of the next financial year. Nothing great would come, in fact it will contribute the initial losses..."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic formulation growth~12–13% for the full year; Q1 may be lower due to high base from Delta waveFY23
Institutional businessFlat; not much growth expectedFY23
Overall topline growth10–12%FY23
EBITDA margin22–22.5%, pressured by additional people, elevated fuel/shipping/inflation costsFY23
Gross margin~68%; may improve if intermediate prices continue softeningFY23
API business growth~10% in FY23; ~15% for next 3 years once Dewas capacity available and regulatory inspections doneFY23 / 3 years
Branded formulation export growth~20%FY23
UK generics revenue~₹60–65 cr from current 13-product basket; could improve with more approvalsFY23
Tax rate~25%FY23 only
Sartan sales returnsSome more may comeQ1 FY23
Dewas plant capitalizationMajor part readyAugust FY23
Dewas plant impactNo significant impact; will start impacting from Q2 FY24, contributing initial losses in the meantimeFY23 / FY24
Lyka injectables stringent-market filings~2-year journey: modifications, quality system assessment, filings first in ROW then stringent markets~2 years

Key Metrics

MetricQ4 FY22
Domestic formulation revenue₹551 cr, +27% YoY from ₹433 cr
Export formulation revenue₹346 cr, +3% YoY from ₹338 cr
Overall API revenue₹258 cr, -15% YoY from ₹260 cr
Gross margin (value addition)70%, vs 72% in Q4 FY21
Full-year gross margin68%, vs 70% in FY21
Impairment provision on investments₹22.46 cr provided in the quarter
Domestic formulation growth outlook FY2312–13%
Overall topline growth guidance FY2310–12%
EBITDA margin guidance FY2322–22.5%
Branded formulation exports growth expectation FY23~20%
API business growth outlook FY2310–12%
Generic business growth outlook FY23~5%
Captive API integration level~56% of turnover
Field force size4,800 medical reps, increasing to ~6,000 in FY23
Cash in balance sheet~₹1,300 cr